去势抵抗前列腺癌-话题@MedSci

#去势抵抗前列腺癌#

12篇内容 | 598人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1946679, encodeId=c14f19466e933, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=221438, objectId=433422143891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=433422143891, replyNumber=0, likeNumber=36, createdTime=2021-12-11, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=433422143891, moduleTitle=Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=433422143891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946680, encodeId=3773194668084, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, objectType=article, longId=299289, objectId=97bb29928916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97bb29928916, replyNumber=0, likeNumber=0, createdTime=2022-12-06, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97bb29928916, moduleTitle=Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97bb29928916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946678, encodeId=b57419466e8bf, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=JAMA Oncol：3期转移性去势抵抗前列腺癌临床试验中患者角度的副作用事件评估, objectType=article, longId=182314, objectId=2a7a18231406, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7a18231406, replyNumber=0, likeNumber=26, createdTime=2019-11-29, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7a18231406, moduleTitle=JAMA Oncol：3期转移性去势抵抗前列腺癌临床试验中患者角度的副作用事件评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7a18231406)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946677, encodeId=d3ca19466e7f9, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=CLIN CANCER RES：Seviteronel治疗去势抵抗前列腺癌患者, objectType=article, longId=153068, objectId=a89e153068ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a89e153068ce, replyNumber=0, likeNumber=27, createdTime=2019-09-30, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a89e153068ce, moduleTitle=CLIN CANCER RES：Seviteronel治疗去势抵抗前列腺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a89e153068ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946673, encodeId=8c8e19466e36b, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=CLIN CANCER RES：靶向去势抵抗前列腺癌中的BET家族蛋白, objectType=article, longId=142734, objectId=e464142e34a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e464142e34a8, replyNumber=0, likeNumber=23, createdTime=2019-06-01, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e464142e34a8, moduleTitle=CLIN CANCER RES：靶向去势抵抗前列腺癌中的BET家族蛋白, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e464142e34a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946674, encodeId=805119466e49b, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=JAMA ONCOL：BIND-014治疗转移性去势抵抗前列腺癌, objectType=article, longId=142736, objectId=0797142e36bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0797142e36bd, replyNumber=0, likeNumber=29, createdTime=2018-07-12, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0797142e36bd, moduleTitle=JAMA ONCOL：BIND-014治疗转移性去势抵抗前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0797142e36bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946675, encodeId=b81219466e5e6, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=JCO：阿比特龙单独或联合恩杂鲁胺治疗转移性去势抵抗前列腺癌, objectType=article, longId=144995, objectId=f9c214499581, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9c214499581, replyNumber=0, likeNumber=32, createdTime=2019-04-24, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9c214499581, moduleTitle=JCO：阿比特龙单独或联合恩杂鲁胺治疗转移性去势抵抗前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9c214499581)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946676, encodeId=b14b19466e6a3, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=CLIN CANCER RES：靶向Galectin-1可以抑制去势抵抗前列腺癌进展, objectType=article, longId=148811, objectId=9fc3148811bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fc3148811bf, replyNumber=0, likeNumber=33, createdTime=2019-07-06, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fc3148811bf, moduleTitle=CLIN CANCER RES：靶向Galectin-1可以抑制去势抵抗前列腺癌进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fc3148811bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946672, encodeId=bf3f19466e215, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=CLIN CANCER RES：PTEN缺失促进去势抵抗前列腺癌瘤内雄激素合成和肿瘤微环境重塑, objectType=article, longId=130858, objectId=a92413085857, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a92413085857, replyNumber=0, likeNumber=30, createdTime=2018-05-09, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a92413085857, moduleTitle=CLIN CANCER RES：PTEN缺失促进去势抵抗前列腺癌瘤内雄激素合成和肿瘤微环境重塑, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a92413085857)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946671, encodeId=75f319466e157, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=JAMA Oncology：PET/CT评估的雄激素受体表达和糖酵解活动作为转移性去势抵抗前列腺癌预后分子标志, objectType=article, longId=121462, objectId=0fdf121462ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fdf121462ae, replyNumber=0, likeNumber=31, createdTime=2018-07-13, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fdf121462ae, moduleTitle=JAMA Oncology：PET/CT评估的雄激素受体表达和糖酵解活动作为转移性去势抵抗前列腺癌预后分子标志, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fdf121462ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946670, encodeId=23c419466e08c, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=Lancet Oncol.：恩杂鲁胺测改善转移性去势抵抗前列腺癌患者生活质量（PREVAIL试验）, objectType=article, longId=50499, objectId=404e50499e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=404e50499e8, replyNumber=0, likeNumber=42, createdTime=2016-03-24, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=404e50499e8, moduleTitle=Lancet Oncol.：恩杂鲁胺测改善转移性去势抵抗前列腺癌患者生活质量（PREVAIL试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=404e50499e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1946669, encodeId=4f99194666934, content=<a href='/topic/show?id=e61f3e232f7' target=_blank style='color:#2F92EE;'>#去势抵抗前列腺癌#</a>, objectTitle=JCO：zibotentan联合多西他赛不能改善转移性去势抵抗前列腺癌患者生存, objectType=article, longId=17694, objectId=01fb1e69483, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01fb1e69483, replyNumber=0, likeNumber=27, createdTime=2013-05-20, rootId=0, userName=more is better!, userId=ca6a2500099, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01fb1e69483, moduleTitle=JCO：zibotentan联合多西他赛不能改善转移性去势抵抗前列腺癌患者生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01fb1e69483)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

去势抵抗前列腺癌

2020-05-29

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

Eur J Cancer：Nivolumab联合多西他赛治疗未经化疗的转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2021-12-11

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

Target Oncol:真实世界评估阿比特龙+泼尼松或泼尼松龙(AAP)一线或二线治疗转移性去势抵抗前列腺癌(mCRPC)的疗效和安全性

2022-12-06

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

JAMA Oncol：3期转移性去势抵抗前列腺癌临床试验中患者角度的副作用事件评估

2019-11-29

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

CLIN CANCER RES：Seviteronel治疗去势抵抗前列腺癌患者

2019-09-30

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

CLIN CANCER RES：靶向去势抵抗前列腺癌中的BET家族蛋白

2019-06-01

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

JAMA ONCOL：BIND-014治疗转移性去势抵抗前列腺癌

2018-07-12

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

JCO：阿比特龙单独或联合恩杂鲁胺治疗转移性去势抵抗前列腺癌

2019-04-24

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

CLIN CANCER RES：靶向Galectin-1可以抑制去势抵抗前列腺癌进展

2019-07-06

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

CLIN CANCER RES：PTEN缺失促进去势抵抗前列腺癌瘤内雄激素合成和肿瘤微环境重塑

2018-05-09

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

JAMA Oncology：PET/CT评估的雄激素受体表达和糖酵解活动作为转移性去势抵抗前列腺癌预后分子标志

2018-07-13

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

Lancet Oncol.：恩杂鲁胺测改善转移性去势抵抗前列腺癌患者生活质量（PREVAIL试验）

2016-03-24

more is better! (审核中...)

前往app查看评论内容

#去势抵抗前列腺癌#

JCO：zibotentan联合多西他赛不能改善转移性去势抵抗前列腺癌患者生存

2013-05-20

科室
- - 订阅+
  - 更多科室
工具
服务